nodes	percent_of_prediction	percent_of_DWPC	metapath
Neostigmine—ABCB1—Mitomycin—urinary bladder cancer	0.277	0.357	CbGbCtD
Neostigmine—BCHE—Cisplatin—urinary bladder cancer	0.228	0.294	CbGbCtD
Neostigmine—ABCB1—Gemcitabine—urinary bladder cancer	0.0797	0.103	CbGbCtD
Neostigmine—ABCB1—Cisplatin—urinary bladder cancer	0.0579	0.0746	CbGbCtD
Neostigmine—ABCB1—Etoposide—urinary bladder cancer	0.0569	0.0733	CbGbCtD
Neostigmine—ABCB1—Doxorubicin—urinary bladder cancer	0.0388	0.05	CbGbCtD
Neostigmine—ABCB1—Methotrexate—urinary bladder cancer	0.0376	0.0484	CbGbCtD
Neostigmine—Coma—Methotrexate—urinary bladder cancer	0.000832	0.00372	CcSEcCtD
Neostigmine—Salivary hypersecretion—Epirubicin—urinary bladder cancer	0.000828	0.0037	CcSEcCtD
Neostigmine—Urinary tract disorder—Cisplatin—urinary bladder cancer	0.000823	0.00368	CcSEcCtD
Neostigmine—Connective tissue disorder—Cisplatin—urinary bladder cancer	0.000819	0.00366	CcSEcCtD
Neostigmine—Urethral disorder—Cisplatin—urinary bladder cancer	0.000817	0.00365	CcSEcCtD
Neostigmine—Atrioventricular block—Doxorubicin—urinary bladder cancer	0.000813	0.00363	CcSEcCtD
Neostigmine—Mediastinal disorder—Gemcitabine—urinary bladder cancer	0.000806	0.0036	CcSEcCtD
Neostigmine—Convulsion—Thiotepa—urinary bladder cancer	0.000802	0.00358	CcSEcCtD
Neostigmine—Arrhythmia—Gemcitabine—urinary bladder cancer	0.000799	0.00357	CcSEcCtD
Neostigmine—Arthralgia—Thiotepa—urinary bladder cancer	0.000788	0.00352	CcSEcCtD
Neostigmine—Arrhythmia—Fluorouracil—urinary bladder cancer	0.000785	0.00351	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.000782	0.0035	CcSEcCtD
Neostigmine—Coma—Epirubicin—urinary bladder cancer	0.000779	0.00348	CcSEcCtD
Neostigmine—Flushing—Cisplatin—urinary bladder cancer	0.000773	0.00346	CcSEcCtD
Neostigmine—Salivary hypersecretion—Doxorubicin—urinary bladder cancer	0.000766	0.00342	CcSEcCtD
Neostigmine—Urinary tract disorder—Etoposide—urinary bladder cancer	0.000754	0.00337	CcSEcCtD
Neostigmine—Mediastinal disorder—Cisplatin—urinary bladder cancer	0.000751	0.00336	CcSEcCtD
Neostigmine—Urethral disorder—Etoposide—urinary bladder cancer	0.000748	0.00334	CcSEcCtD
Neostigmine—Arrhythmia—Cisplatin—urinary bladder cancer	0.000744	0.00333	CcSEcCtD
Neostigmine—Nervous system disorder—Thiotepa—urinary bladder cancer	0.00074	0.00331	CcSEcCtD
Neostigmine—Tachycardia—Thiotepa—urinary bladder cancer	0.000737	0.00329	CcSEcCtD
Neostigmine—Skin disorder—Thiotepa—urinary bladder cancer	0.000733	0.00328	CcSEcCtD
Neostigmine—Coma—Doxorubicin—urinary bladder cancer	0.00072	0.00322	CcSEcCtD
Neostigmine—Flatulence—Cisplatin—urinary bladder cancer	0.000715	0.00319	CcSEcCtD
Neostigmine—Flushing—Etoposide—urinary bladder cancer	0.000708	0.00317	CcSEcCtD
Neostigmine—Muscle spasms—Cisplatin—urinary bladder cancer	0.000697	0.00312	CcSEcCtD
Neostigmine—Mediastinal disorder—Etoposide—urinary bladder cancer	0.000688	0.00307	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.000688	0.00307	CcSEcCtD
Neostigmine—Somnolence—Thiotepa—urinary bladder cancer	0.000671	0.003	CcSEcCtD
Neostigmine—Convulsion—Fluorouracil—urinary bladder cancer	0.000663	0.00296	CcSEcCtD
Neostigmine—Arthralgia—Gemcitabine—urinary bladder cancer	0.000663	0.00296	CcSEcCtD
Neostigmine—Osteoarthritis—Methotrexate—urinary bladder cancer	0.000661	0.00295	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.000658	0.00294	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000652	0.00291	CcSEcCtD
Neostigmine—Muscle spasms—Etoposide—urinary bladder cancer	0.000639	0.00286	CcSEcCtD
Neostigmine—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.000635	0.00284	CcSEcCtD
Neostigmine—Convulsion—Cisplatin—urinary bladder cancer	0.000628	0.00281	CcSEcCtD
Neostigmine—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.000624	0.00279	CcSEcCtD
Neostigmine—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.000623	0.00278	CcSEcCtD
Neostigmine—Osteoarthritis—Epirubicin—urinary bladder cancer	0.000619	0.00276	CcSEcCtD
Neostigmine—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.000617	0.00276	CcSEcCtD
Neostigmine—Skin disorder—Gemcitabine—urinary bladder cancer	0.000617	0.00276	CcSEcCtD
Neostigmine—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.000614	0.00274	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000613	0.00274	CcSEcCtD
Neostigmine—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.000612	0.00274	CcSEcCtD
Neostigmine—Tachycardia—Fluorouracil—urinary bladder cancer	0.000609	0.00272	CcSEcCtD
Neostigmine—Urticaria—Thiotepa—urinary bladder cancer	0.0006	0.00268	CcSEcCtD
Neostigmine—Abdominal pain—Thiotepa—urinary bladder cancer	0.000597	0.00267	CcSEcCtD
Neostigmine—Hypotension—Gemcitabine—urinary bladder cancer	0.000593	0.00265	CcSEcCtD
Neostigmine—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000592	0.00265	CcSEcCtD
Neostigmine—Cardiac arrest—Epirubicin—urinary bladder cancer	0.000588	0.00263	CcSEcCtD
Neostigmine—Loss of consciousness—Etoposide—urinary bladder cancer	0.000584	0.00261	CcSEcCtD
Neostigmine—Hypotension—Fluorouracil—urinary bladder cancer	0.000584	0.00261	CcSEcCtD
Neostigmine—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000581	0.00259	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000579	0.00259	CcSEcCtD
Neostigmine—Tachycardia—Cisplatin—urinary bladder cancer	0.000578	0.00258	CcSEcCtD
Neostigmine—Convulsion—Etoposide—urinary bladder cancer	0.000576	0.00257	CcSEcCtD
Neostigmine—Skin disorder—Cisplatin—urinary bladder cancer	0.000575	0.00257	CcSEcCtD
Neostigmine—Insomnia—Gemcitabine—urinary bladder cancer	0.000574	0.00257	CcSEcCtD
Neostigmine—Osteoarthritis—Doxorubicin—urinary bladder cancer	0.000572	0.00256	CcSEcCtD
Neostigmine—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.000572	0.00256	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000569	0.00254	CcSEcCtD
Neostigmine—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000566	0.00253	CcSEcCtD
Neostigmine—Insomnia—Fluorouracil—urinary bladder cancer	0.000565	0.00252	CcSEcCtD
Neostigmine—Somnolence—Gemcitabine—urinary bladder cancer	0.000565	0.00252	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000562	0.00251	CcSEcCtD
Neostigmine—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000557	0.00249	CcSEcCtD
Neostigmine—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000556	0.00249	CcSEcCtD
Neostigmine—Somnolence—Fluorouracil—urinary bladder cancer	0.000555	0.00248	CcSEcCtD
Neostigmine—Hypotension—Cisplatin—urinary bladder cancer	0.000553	0.00247	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000548	0.00245	CcSEcCtD
Neostigmine—Cardiac arrest—Doxorubicin—urinary bladder cancer	0.000544	0.00243	CcSEcCtD
Neostigmine—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000542	0.00242	CcSEcCtD
Neostigmine—Asthenia—Thiotepa—urinary bladder cancer	0.000542	0.00242	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000539	0.00241	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000539	0.00241	CcSEcCtD
Neostigmine—Pruritus—Thiotepa—urinary bladder cancer	0.000534	0.00239	CcSEcCtD
Neostigmine—Tachycardia—Etoposide—urinary bladder cancer	0.000529	0.00237	CcSEcCtD
Neostigmine—Dyspnoea—Cisplatin—urinary bladder cancer	0.000528	0.00236	CcSEcCtD
Neostigmine—Skin disorder—Etoposide—urinary bladder cancer	0.000527	0.00235	CcSEcCtD
Neostigmine—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000524	0.00234	CcSEcCtD
Neostigmine—Diarrhoea—Thiotepa—urinary bladder cancer	0.000517	0.00231	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000511	0.00228	CcSEcCtD
Neostigmine—Drowsiness—Methotrexate—urinary bladder cancer	0.000509	0.00228	CcSEcCtD
Neostigmine—Hypotension—Etoposide—urinary bladder cancer	0.000507	0.00226	CcSEcCtD
Neostigmine—Dizziness—Thiotepa—urinary bladder cancer	0.000499	0.00223	CcSEcCtD
Neostigmine—Urticaria—Fluorouracil—urinary bladder cancer	0.000496	0.00222	CcSEcCtD
Neostigmine—Pollakiuria—Epirubicin—urinary bladder cancer	0.000494	0.00221	CcSEcCtD
Neostigmine—Dyspnoea—Etoposide—urinary bladder cancer	0.000484	0.00216	CcSEcCtD
Neostigmine—Somnolence—Etoposide—urinary bladder cancer	0.000482	0.00215	CcSEcCtD
Neostigmine—Vomiting—Thiotepa—urinary bladder cancer	0.00048	0.00215	CcSEcCtD
Neostigmine—Drowsiness—Epirubicin—urinary bladder cancer	0.000477	0.00213	CcSEcCtD
Neostigmine—Rash—Thiotepa—urinary bladder cancer	0.000476	0.00213	CcSEcCtD
Neostigmine—Dermatitis—Thiotepa—urinary bladder cancer	0.000476	0.00213	CcSEcCtD
Neostigmine—Headache—Thiotepa—urinary bladder cancer	0.000473	0.00211	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000468	0.00209	CcSEcCtD
Neostigmine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00046	0.00206	CcSEcCtD
Neostigmine—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000457	0.00204	CcSEcCtD
Neostigmine—Asthenia—Gemcitabine—urinary bladder cancer	0.000456	0.00204	CcSEcCtD
Neostigmine—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000452	0.00202	CcSEcCtD
Neostigmine—Pruritus—Gemcitabine—urinary bladder cancer	0.000449	0.00201	CcSEcCtD
Neostigmine—Nausea—Thiotepa—urinary bladder cancer	0.000448	0.002	CcSEcCtD
Neostigmine—Urethral disorder—Methotrexate—urinary bladder cancer	0.000448	0.002	CcSEcCtD
Neostigmine—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000443	0.00198	CcSEcCtD
Neostigmine—Pruritus—Fluorouracil—urinary bladder cancer	0.000442	0.00197	CcSEcCtD
Neostigmine—Drowsiness—Doxorubicin—urinary bladder cancer	0.000441	0.00197	CcSEcCtD
Neostigmine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000436	0.00195	CcSEcCtD
Neostigmine—Bradycardia—Epirubicin—urinary bladder cancer	0.000436	0.00195	CcSEcCtD
Neostigmine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000435	0.00194	CcSEcCtD
Neostigmine—Urticaria—Etoposide—urinary bladder cancer	0.000431	0.00193	CcSEcCtD
Neostigmine—Abdominal pain—Etoposide—urinary bladder cancer	0.000429	0.00192	CcSEcCtD
Neostigmine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000427	0.00191	CcSEcCtD
Neostigmine—Asthenia—Cisplatin—urinary bladder cancer	0.000425	0.0019	CcSEcCtD
Neostigmine—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000423	0.00189	CcSEcCtD
Neostigmine—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.00042	0.00188	CcSEcCtD
Neostigmine—Urethral disorder—Epirubicin—urinary bladder cancer	0.000419	0.00187	CcSEcCtD
Neostigmine—Dizziness—Fluorouracil—urinary bladder cancer	0.000413	0.00185	CcSEcCtD
Neostigmine—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000412	0.00184	CcSEcCtD
Neostigmine—Diarrhoea—Cisplatin—urinary bladder cancer	0.000405	0.00181	CcSEcCtD
Neostigmine—Vomiting—Gemcitabine—urinary bladder cancer	0.000404	0.0018	CcSEcCtD
Neostigmine—Bradycardia—Doxorubicin—urinary bladder cancer	0.000403	0.0018	CcSEcCtD
Neostigmine—Mental disorder—Methotrexate—urinary bladder cancer	0.000401	0.00179	CcSEcCtD
Neostigmine—Rash—Gemcitabine—urinary bladder cancer	0.0004	0.00179	CcSEcCtD
Neostigmine—Dermatitis—Gemcitabine—urinary bladder cancer	0.0004	0.00179	CcSEcCtD
Neostigmine—Hypersensitivity—Etoposide—urinary bladder cancer	0.0004	0.00179	CcSEcCtD
Neostigmine—Headache—Gemcitabine—urinary bladder cancer	0.000398	0.00178	CcSEcCtD
Neostigmine—Flushing—Epirubicin—urinary bladder cancer	0.000397	0.00177	CcSEcCtD
Neostigmine—Vomiting—Fluorouracil—urinary bladder cancer	0.000397	0.00177	CcSEcCtD
Neostigmine—Rash—Fluorouracil—urinary bladder cancer	0.000394	0.00176	CcSEcCtD
Neostigmine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000393	0.00176	CcSEcCtD
Neostigmine—Headache—Fluorouracil—urinary bladder cancer	0.000391	0.00175	CcSEcCtD
Neostigmine—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000391	0.00175	CcSEcCtD
Neostigmine—Asthenia—Etoposide—urinary bladder cancer	0.000389	0.00174	CcSEcCtD
Neostigmine—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000389	0.00174	CcSEcCtD
Neostigmine—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000388	0.00173	CcSEcCtD
Neostigmine—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000386	0.00172	CcSEcCtD
Neostigmine—Pruritus—Etoposide—urinary bladder cancer	0.000384	0.00171	CcSEcCtD
Neostigmine—Arrhythmia—Epirubicin—urinary bladder cancer	0.000382	0.00171	CcSEcCtD
Neostigmine—Nausea—Gemcitabine—urinary bladder cancer	0.000377	0.00169	CcSEcCtD
Neostigmine—Vomiting—Cisplatin—urinary bladder cancer	0.000376	0.00168	CcSEcCtD
Neostigmine—Mental disorder—Epirubicin—urinary bladder cancer	0.000375	0.00168	CcSEcCtD
Neostigmine—Rash—Cisplatin—urinary bladder cancer	0.000373	0.00167	CcSEcCtD
Neostigmine—Dermatitis—Cisplatin—urinary bladder cancer	0.000373	0.00167	CcSEcCtD
Neostigmine—Diarrhoea—Etoposide—urinary bladder cancer	0.000371	0.00166	CcSEcCtD
Neostigmine—Nausea—Fluorouracil—urinary bladder cancer	0.000371	0.00166	CcSEcCtD
Neostigmine—Flushing—Doxorubicin—urinary bladder cancer	0.000367	0.00164	CcSEcCtD
Neostigmine—Flatulence—Epirubicin—urinary bladder cancer	0.000367	0.00164	CcSEcCtD
Neostigmine—Dizziness—Etoposide—urinary bladder cancer	0.000359	0.0016	CcSEcCtD
Neostigmine—Muscle spasms—Epirubicin—urinary bladder cancer	0.000358	0.0016	CcSEcCtD
Neostigmine—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000357	0.00159	CcSEcCtD
Neostigmine—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000354	0.00158	CcSEcCtD
Neostigmine—Nausea—Cisplatin—urinary bladder cancer	0.000352	0.00157	CcSEcCtD
Neostigmine—Mental disorder—Doxorubicin—urinary bladder cancer	0.000347	0.00155	CcSEcCtD
Neostigmine—Convulsion—Methotrexate—urinary bladder cancer	0.000345	0.00154	CcSEcCtD
Neostigmine—Vomiting—Etoposide—urinary bladder cancer	0.000345	0.00154	CcSEcCtD
Neostigmine—Agitation—Epirubicin—urinary bladder cancer	0.000342	0.00153	CcSEcCtD
Neostigmine—Rash—Etoposide—urinary bladder cancer	0.000342	0.00153	CcSEcCtD
Neostigmine—Dermatitis—Etoposide—urinary bladder cancer	0.000342	0.00153	CcSEcCtD
Neostigmine—Headache—Etoposide—urinary bladder cancer	0.00034	0.00152	CcSEcCtD
Neostigmine—Flatulence—Doxorubicin—urinary bladder cancer	0.00034	0.00152	CcSEcCtD
Neostigmine—Arthralgia—Methotrexate—urinary bladder cancer	0.000339	0.00151	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000337	0.0015	CcSEcCtD
Neostigmine—Syncope—Epirubicin—urinary bladder cancer	0.000334	0.00149	CcSEcCtD
Neostigmine—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000331	0.00148	CcSEcCtD
Neostigmine—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000327	0.00146	CcSEcCtD
Neostigmine—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000325	0.00145	CcSEcCtD
Neostigmine—Convulsion—Epirubicin—urinary bladder cancer	0.000323	0.00144	CcSEcCtD
Neostigmine—Nausea—Etoposide—urinary bladder cancer	0.000322	0.00144	CcSEcCtD
Neostigmine—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000319	0.00142	CcSEcCtD
Neostigmine—Arthralgia—Epirubicin—urinary bladder cancer	0.000317	0.00142	CcSEcCtD
Neostigmine—Agitation—Doxorubicin—urinary bladder cancer	0.000317	0.00142	CcSEcCtD
Neostigmine—Skin disorder—Methotrexate—urinary bladder cancer	0.000316	0.00141	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000315	0.00141	CcSEcCtD
Neostigmine—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000314	0.0014	CcSEcCtD
Neostigmine—Dry mouth—Epirubicin—urinary bladder cancer	0.00031	0.00139	CcSEcCtD
Neostigmine—Syncope—Doxorubicin—urinary bladder cancer	0.000309	0.00138	CcSEcCtD
Neostigmine—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000304	0.00136	CcSEcCtD
Neostigmine—Hypotension—Methotrexate—urinary bladder cancer	0.000304	0.00136	CcSEcCtD
Neostigmine—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000303	0.00135	CcSEcCtD
Neostigmine—Shock—Epirubicin—urinary bladder cancer	0.000299	0.00134	CcSEcCtD
Neostigmine—Convulsion—Doxorubicin—urinary bladder cancer	0.000299	0.00133	CcSEcCtD
Neostigmine—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000298	0.00133	CcSEcCtD
Neostigmine—Tachycardia—Epirubicin—urinary bladder cancer	0.000297	0.00133	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000296	0.00132	CcSEcCtD
Neostigmine—Skin disorder—Epirubicin—urinary bladder cancer	0.000295	0.00132	CcSEcCtD
Neostigmine—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000294	0.00131	CcSEcCtD
Neostigmine—Insomnia—Methotrexate—urinary bladder cancer	0.000294	0.00131	CcSEcCtD
Neostigmine—Arthralgia—Doxorubicin—urinary bladder cancer	0.000293	0.00131	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000291	0.0013	CcSEcCtD
Neostigmine—Dyspnoea—Methotrexate—urinary bladder cancer	0.00029	0.00129	CcSEcCtD
Neostigmine—Somnolence—Methotrexate—urinary bladder cancer	0.000289	0.00129	CcSEcCtD
Neostigmine—Dry mouth—Doxorubicin—urinary bladder cancer	0.000287	0.00128	CcSEcCtD
Neostigmine—Hypotension—Epirubicin—urinary bladder cancer	0.000284	0.00127	CcSEcCtD
Neostigmine—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000281	0.00126	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.00028	0.00125	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000277	0.00124	CcSEcCtD
Neostigmine—Shock—Doxorubicin—urinary bladder cancer	0.000277	0.00124	CcSEcCtD
Neostigmine—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000276	0.00123	CcSEcCtD
Neostigmine—Insomnia—Epirubicin—urinary bladder cancer	0.000275	0.00123	CcSEcCtD
Neostigmine—Tachycardia—Doxorubicin—urinary bladder cancer	0.000275	0.00123	CcSEcCtD
Neostigmine—Skin disorder—Doxorubicin—urinary bladder cancer	0.000273	0.00122	CcSEcCtD
Neostigmine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000272	0.00122	CcSEcCtD
Neostigmine—Dyspnoea—Epirubicin—urinary bladder cancer	0.000271	0.00121	CcSEcCtD
Neostigmine—Somnolence—Epirubicin—urinary bladder cancer	0.00027	0.00121	CcSEcCtD
Neostigmine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000266	0.00119	CcSEcCtD
Neostigmine—Hypotension—Doxorubicin—urinary bladder cancer	0.000263	0.00117	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000262	0.00117	CcSEcCtD
Neostigmine—Urticaria—Methotrexate—urinary bladder cancer	0.000258	0.00115	CcSEcCtD
Neostigmine—Abdominal pain—Methotrexate—urinary bladder cancer	0.000257	0.00115	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000256	0.00115	CcSEcCtD
Neostigmine—Insomnia—Doxorubicin—urinary bladder cancer	0.000254	0.00114	CcSEcCtD
Neostigmine—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000251	0.00112	CcSEcCtD
Neostigmine—Somnolence—Doxorubicin—urinary bladder cancer	0.00025	0.00112	CcSEcCtD
Neostigmine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000249	0.00111	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000243	0.00109	CcSEcCtD
Neostigmine—Urticaria—Epirubicin—urinary bladder cancer	0.000242	0.00108	CcSEcCtD
Neostigmine—Abdominal pain—Epirubicin—urinary bladder cancer	0.00024	0.00107	CcSEcCtD
Neostigmine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000239	0.00107	CcSEcCtD
Neostigmine—Asthenia—Methotrexate—urinary bladder cancer	0.000233	0.00104	CcSEcCtD
Neostigmine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.00023	0.00103	CcSEcCtD
Neostigmine—Pruritus—Methotrexate—urinary bladder cancer	0.00023	0.00103	CcSEcCtD
Neostigmine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000224	0.001	CcSEcCtD
Neostigmine—Urticaria—Doxorubicin—urinary bladder cancer	0.000223	0.000999	CcSEcCtD
Neostigmine—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000222	0.000994	CcSEcCtD
Neostigmine—Diarrhoea—Methotrexate—urinary bladder cancer	0.000222	0.000993	CcSEcCtD
Neostigmine—Asthenia—Epirubicin—urinary bladder cancer	0.000218	0.000975	CcSEcCtD
Neostigmine—Pruritus—Epirubicin—urinary bladder cancer	0.000215	0.000961	CcSEcCtD
Neostigmine—Dizziness—Methotrexate—urinary bladder cancer	0.000215	0.00096	CcSEcCtD
Neostigmine—Diarrhoea—Epirubicin—urinary bladder cancer	0.000208	0.00093	CcSEcCtD
Neostigmine—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000207	0.000926	CcSEcCtD
Neostigmine—Vomiting—Methotrexate—urinary bladder cancer	0.000207	0.000923	CcSEcCtD
Neostigmine—Rash—Methotrexate—urinary bladder cancer	0.000205	0.000915	CcSEcCtD
Neostigmine—Dermatitis—Methotrexate—urinary bladder cancer	0.000205	0.000915	CcSEcCtD
Neostigmine—Headache—Methotrexate—urinary bladder cancer	0.000204	0.00091	CcSEcCtD
Neostigmine—Asthenia—Doxorubicin—urinary bladder cancer	0.000202	0.000902	CcSEcCtD
Neostigmine—Dizziness—Epirubicin—urinary bladder cancer	0.000201	0.000898	CcSEcCtD
Neostigmine—Pruritus—Doxorubicin—urinary bladder cancer	0.000199	0.000889	CcSEcCtD
Neostigmine—Vomiting—Epirubicin—urinary bladder cancer	0.000193	0.000864	CcSEcCtD
Neostigmine—Nausea—Methotrexate—urinary bladder cancer	0.000193	0.000862	CcSEcCtD
Neostigmine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000192	0.00086	CcSEcCtD
Neostigmine—Rash—Epirubicin—urinary bladder cancer	0.000192	0.000857	CcSEcCtD
Neostigmine—Dermatitis—Epirubicin—urinary bladder cancer	0.000192	0.000856	CcSEcCtD
Neostigmine—Headache—Epirubicin—urinary bladder cancer	0.00019	0.000851	CcSEcCtD
Neostigmine—Dizziness—Doxorubicin—urinary bladder cancer	0.000186	0.000831	CcSEcCtD
Neostigmine—Nausea—Epirubicin—urinary bladder cancer	0.000181	0.000807	CcSEcCtD
Neostigmine—Vomiting—Doxorubicin—urinary bladder cancer	0.000179	0.000799	CcSEcCtD
Neostigmine—Rash—Doxorubicin—urinary bladder cancer	0.000177	0.000793	CcSEcCtD
Neostigmine—Dermatitis—Doxorubicin—urinary bladder cancer	0.000177	0.000792	CcSEcCtD
Neostigmine—Headache—Doxorubicin—urinary bladder cancer	0.000176	0.000788	CcSEcCtD
Neostigmine—Nausea—Doxorubicin—urinary bladder cancer	0.000167	0.000747	CcSEcCtD
